Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ROY F CHEMALY and DIMPY JAGDISH SHAH.
Connection Strength

6.832
  1. Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Lett. 2016 08 28; 379(1):100-6.
    View in: PubMed
    Score: 0.555
  2. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Lett. 2016 Jan 28; 370(2):358-64.
    View in: PubMed
    Score: 0.535
  3. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood. 2014 May 22; 123(21):3263-8.
    View in: PubMed
    Score: 0.478
  4. Reply to Robinson. J Infect Dis. 2013 Sep 01; 208(5):864-5.
    View in: PubMed
    Score: 0.453
  5. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013 Aug; 68(8):1872-80.
    View in: PubMed
    Score: 0.447
  6. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res. 2012; 2(4):203-18.
    View in: PubMed
    Score: 0.435
  7. Characteristics and outcomes of pandemic 2009/H1N1 versus seasonal influenza in children with cancer. Pediatr Infect Dis J. 2012 Apr; 31(4):373-8.
    View in: PubMed
    Score: 0.416
  8. Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant. Open Forum Infect Dis. 2023 Aug; 10(8):ofad386.
    View in: PubMed
    Score: 0.228
  9. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. Clin Infect Dis. 2020 12 03; 71(9):2365-2374.
    View in: PubMed
    Score: 0.190
  10. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2019 02 23; 219(6):898-907.
    View in: PubMed
    Score: 0.168
  11. Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2019 04; 25(4):800-809.
    View in: PubMed
    Score: 0.165
  12. Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection. J Antimicrob Chemother. 2018 11 01; 73(11):3162-3169.
    View in: PubMed
    Score: 0.164
  13. Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. Transpl Infect Dis. 2018 Dec; 20(6):e12994.
    View in: PubMed
    Score: 0.163
  14. Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. J Med Virol. 2018 01; 90(1):50-60.
    View in: PubMed
    Score: 0.152
  15. Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes. Cancer. 2017 Jun 15; 123(12):2329-2337.
    View in: PubMed
    Score: 0.146
  16. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016 12 08; 128(23):2624-2636.
    View in: PubMed
    Score: 0.143
  17. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. Antiviral Res. 2016 11; 135:91-96.
    View in: PubMed
    Score: 0.141
  18. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. Antiviral Res. 2016 10; 134:58-62.
    View in: PubMed
    Score: 0.141
  19. Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. J Mol Diagn. 2016 09; 18(5):638-642.
    View in: PubMed
    Score: 0.140
  20. Utility of the Enzyme-Linked Immunospot Interferon-?-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2016 Jun 01; 213(11):1701-7.
    View in: PubMed
    Score: 0.136
  21. Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index. Biol Blood Marrow Transplant. 2016 Mar; 22(3):542-8.
    View in: PubMed
    Score: 0.134
  22. Influenza vaccination in patients with cancer: factors associated with vaccination practices for patients and their household members. Infect Control Hosp Epidemiol. 2015 Oct; 36(10):1239-41.
    View in: PubMed
    Score: 0.130
  23. Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis. 2014 Dec; 16(6):878-86.
    View in: PubMed
    Score: 0.125
  24. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014 Nov 15; 59 Suppl 5:S344-51.
    View in: PubMed
    Score: 0.125
  25. Cluster and sporadic cases of herbaspirillum species infections in patients with cancer. Clin Infect Dis. 2015 Jan 01; 60(1):48-54.
    View in: PubMed
    Score: 0.123
  26. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol. 2014 Aug; 36(6):e376-81.
    View in: PubMed
    Score: 0.122
  27. Reply to F?tkenheuer et al. J Infect Dis. 2013 May 15; 207(10):1622-3.
    View in: PubMed
    Score: 0.111
  28. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis. 2012 Nov; 206(9):1367-71.
    View in: PubMed
    Score: 0.107
  29. Inter and intra-host diversity of RSV in hematopoietic stem cell transplant adults with normal and delayed viral clearance. Virus Evol. 2024; 10(1):vead086.
    View in: PubMed
    Score: 0.059
  30. Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. Viruses. 2021 05 26; 13(6).
    View in: PubMed
    Score: 0.049
  31. Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. Vaccines (Basel). 2020 Apr 21; 8(2).
    View in: PubMed
    Score: 0.045
  32. Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-A-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans. J Infect Dis. 2020 02 03; 221(4):636-646.
    View in: PubMed
    Score: 0.045
  33. Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. Open Forum Infect Dis. 2019 May; 6(5):ofz173.
    View in: PubMed
    Score: 0.042
  34. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults. Front Immunol. 2019; 10:706.
    View in: PubMed
    Score: 0.042
  35. Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. PLoS One. 2018; 13(5):e0197418.
    View in: PubMed
    Score: 0.040
  36. Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients. J Infect Dis. 2018 03 28; 217(8):1247-1256.
    View in: PubMed
    Score: 0.039
  37. Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients. Am J Infect Control. 2016 09 01; 44(9):1016-21.
    View in: PubMed
    Score: 0.035
  38. Utility of routine surveillance blood cultures in asymptomatic allogeneic hematopoietic stem cell transplant recipients with indwelling central venous catheters at a comprehensive cancer center. Am J Infect Control. 2014 Oct; 42(10):1084-8.
    View in: PubMed
    Score: 0.031
  39. Infection with novel respiratory syncytial virus genotype Ontario (ON1) in adult hematopoietic cell transplant recipients, Texas, 2011-2013. J Infect Dis. 2015 Feb 15; 211(4):582-9.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.